Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents

Marta Cesca, Francesca Bizzaro, Massimo Zucchetti, Raffaella Giavazzi

Research output: Contribution to journalArticlepeer-review

Abstract

Numerous angiogenesis-vascular targeting agents have been admitted to the ranks of cancer therapeutics; most are used in polytherapy regimens. This review looks at recent progress and our own preclinical experience in combining angiogenesis inhibitors, mainly acting on VEGF/VEGFR pathways, and vascular targeting agents with conventional chemotherapy, discussing the factors that determine the outcome of these treatments. Molecular and morphological modifications of the tumor microenvironment associated with drug distribution and activity are reviewed. Modalities to improve drug delivery and strategies for optimizing combination therapy are examined.

Original languageEnglish
Article numberArticle 259
JournalFrontiers in Oncology
Volume3 OCT
DOIs
Publication statusPublished - 2013

Keywords

  • Angiogenesis inhibitors
  • Combination therapies
  • Drug delivery
  • Paclitaxel
  • Tumor microenvironment
  • Tyrosine kinase receptor inhibitors
  • Vascular disrupting agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents'. Together they form a unique fingerprint.

Cite this